GO:0007197 adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway

The adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway (GO:0007197) is a fundamental biological process in which acetylcholine, a major neurotransmitter, binds to specific G protein-coupled receptors (GPCRs) that are coupled to the Gi/o family of G proteins. This binding leads to the inhibition of adenylate cyclase (also known as adenylyl cyclase), the enzyme responsible for converting ATP to cyclic AMP (cAMP). As a result, intracellular cAMP levels decrease, which in turn modulates downstream effectors such as protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPAC). This pathway is critical for regulating neuronal excitability, heart rate, and smooth muscle contraction, and its dysfunction has been linked to various diseases, including Alzheimer's disease and cardiovascular disorders [1,2]. Understanding GO:0007197 is essential for researchers studying cholinergic signaling, as it represents a key mechanism by which acetylcholine can exert inhibitory effects on cellular activity. The pathway is primarily mediated by muscarinic acetylcholine receptors, particularly the M2 and M4 subtypes, which are known to couple to Gi/o proteins. These receptors are widely expressed in the central nervous system and peripheral tissues, where they fine-tune physiological responses. Recent studies using network pharmacology have highlighted the relevance of this pathway in the context of Alzheimer's disease, where modulation of cholinergic signaling may offer therapeutic benefits [1,2]. Given its broad physiological impact, GO:0007197 is a focal point for drug discovery and functional genomics. Researchers can interrogate this pathway using a variety of molecular and cellular techniques, including CRISPR-based gene editing, to determine the causal roles of individual components. This article provides a comprehensive overview of the pathway's definition, mechanism, key genes, regulation, disease associations, and experimental models, with a focus on how CRISPR technologies can accelerate discovery.

GO:0007197 is defined as an adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by acetylcholine binding to its receptor, and ending with the regulation of a downstream cellular process. In simpler terms, it is a signaling cascade that starts when acetylcholine docks onto a specific type of receptor on the cell surface, leading to the suppression of cAMP production inside the cell. This pathway is synonymous with muscarinic acetylcholine receptor signaling that inhibits adenylate cyclase, reflecting its primary mode of action through Gi/o-coupled muscarinic receptors.

GO:0007197 is critically important because it represents a major mechanism by which the parasympathetic nervous system and cholinergic signaling modulate organ function and neuronal activity. Dysregulation of this pathway has been implicated in Alzheimer's disease, where cholinergic deficits are a hallmark, as well as in cardiac arrhythmias, asthma, and gastrointestinal disorders [1,2]. Understanding the precise molecular players and their regulation can inform the development of targeted therapies, and CRISPR-based models offer powerful tools to dissect causality.

The following genes encode the core receptors, G proteins, and effector enzymes that constitute the adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway.

The adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway is tightly regulated at multiple levels. Receptor availability and sensitivity are controlled by transcriptional regulation of CHRM2 and CHRM4 genes, as well as by desensitization mechanisms involving GRK-mediated phosphorylation and arrestin recruitment. The G protein cycle is regulated by regulators of G protein signaling (RGS) proteins, which accelerate GTP hydrolysis on Gαi/o, thereby terminating the signal. Additionally, adenylate cyclase activity is subject to regulation by other signaling pathways, such as Gs-coupled receptors that stimulate cAMP production, creating a balance between stimulatory and inhibitory inputs. Cross-talk with other GPCRs, such as adenosine or adrenergic receptors, can modulate the pathway's output. Furthermore, phosphodiesterases (PDEs) degrade cAMP, providing another layer of control. In disease states, such as Alzheimer's disease, cholinergic deficits and alterations in receptor expression can disrupt this regulation [1,2].

Alzheimer's disease is characterized by progressive cognitive decline and loss of cholinergic neurons in the basal forebrain. The adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway is directly implicated because muscarinic M2 autoreceptors, which inhibit cAMP, regulate acetylcholine release. In Alzheimer's disease, impaired M2 receptor function may contribute to cholinergic dysfunction. Network pharmacology studies have identified this pathway as a target of natural compounds used in Alzheimer's disease treatment, such as those in Qiong Yu Gao and Citrus grandis essential oil [1,2]. These studies suggest that modulating this pathway could enhance cholinergic transmission and provide therapeutic benefits.

In the heart, M2 muscarinic receptors coupled to Gi/o mediate vagal inhibition of heart rate by reducing cAMP and inhibiting pacemaker currents. Dysregulation of this pathway can lead to arrhythmias, such as atrial fibrillation, and heart failure. Genetic variants in CHRM2 have been associated with altered heart rate variability and susceptibility to cardiac disorders. Targeting this pathway with agonists or antagonists is a potential therapeutic strategy for cardiovascular diseases.

Beyond Alzheimer's disease, this pathway has been implicated in Parkinson's disease, schizophrenia, and addiction. M4 muscarinic receptors are highly expressed in the striatum and modulate dopamine release; their dysfunction is linked to motor and reward deficits. Studies using network pharmacology have highlighted the relevance of this pathway in neurological conditions [1,2]. CRISPR-based models can help dissect the specific contributions of M4 and downstream effectors to these disorders.

Direct measurement of intracellular cAMP levels using ELISA, FRET-based biosensors (e.g., Epac1-camps), or luminescence assays is the gold standard for assessing adenylate cyclase inhibition. These assays can be performed in cell lines expressing muscarinic receptors and Gi/o proteins, and are used to validate the effects of receptor agonists/antagonists or gene knockouts.

RNA sequencing can reveal changes in gene expression following activation or inhibition of the pathway. For example, knockdown of CHRM2 or GNAI1 may alter expression of cAMP-responsive genes. This method is useful for identifying downstream transcriptional networks and potential feedback mechanisms.

Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation status of downstream effectors such as PKA substrates. This approach helps map the signaling cascade and identify novel components. It is particularly powerful when combined with CRISPR knockout of specific genes.

Genome-wide CRISPR knockout or activation screens can identify genes that modulate the pathway's activity. For instance, a screen using a cAMP-responsive reporter can uncover novel regulators of adenylate cyclase inhibition. This unbiased approach accelerates target discovery and functional annotation.

Researchers studying adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in the pathway or in disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic studies.

The adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway (GO:0007197) is a central mechanism in cholinergic signaling, with profound effects on neuronal, cardiac, and smooth muscle function. Its dysregulation is implicated in Alzheimer's disease, cardiovascular disorders, and other conditions, making it a prime target for therapeutic intervention. Advances in CRISPR gene editing now allow precise interrogation of the pathway's components, from receptors to downstream effectors, in physiologically relevant models. By leveraging these tools, researchers can uncover novel drug targets and deepen our understanding of cholinergic biology.